Asuragen & Wave Life Sciences unite for development of HD diagnostics
Category: #health  | By Nikita Chaurasia  | Date: 2019-11-26 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Asuragen & Wave Life Sciences unite for development of HD diagnostics

It has been reported that various industry giants across the medical fraternity have been involved in the mergers and collaborations to develop and commercialize the treatments for distinguished disorders and diseases. In a light of this, Asuragen and Wave Life Sciences have come together to develop diagnostics for Huntington’s disease.

Austin based molecular diagnostic company, Asuragen has partnered with Wave Life Sciences, a clinical stage genetic medicines company, for the commercialization and manufacturing of the companion diagnostics for Huntington’s disease. For the record, Huntington’s disease is a disorder which is caused by an expansion od CAG repeats in the HTT gene. This results in the gradual breakdown of nerve cells in the brain whilst completely weakening the survivor’s physical and mental abilities.

As per reliable sources, the diagnostics which Asuragen would develop is built on the experience gathered by Wave via a single- nucleotide polymorphism phasing methodology. Through this alliance, Wave targets to utilize Asuragen’s market dominant repetitive sequence diagnostic know-how to deliver scalable SNP phasing to aid global Phase 3 development programs and future commercialization globally.

Speaking on the matter, Jaya Gopal, the VP of Bioanalytics, Pharmacology, and Biomarker Development at Wave’s reportedly stated that the company’s unison with Asuragen for companion diagnostic development is a perfect fit owing to its in depth understanding and expertise with complex molecular targets. Asuragen’s expanding presence in the neurogenetics testing market is also an add on for the Wave.

Meanwhile, the President and CEO of Asuragen, Matthew McManus cited that the company was pleased to a part of the novel category of potential therapies to render a positive impact on HD. He further added that developing a companion diagnostic for Wave’s represents the advancement of the latter company’s product portfolio.

Estimates claim that Wave have currently been conducting two Phase clinical trials, PRECISION-HD1 and PRECISION-HD 2, for the patients suffering from HD. These trials are assessing WVE-120101 & WVE-120102 oligonucleotides, which are designed to reduce the mutant HTT mRNA record.
 

Source credit: https://finance.yahoo.com/news/asuragen-partners-wave-life-sciences-130000639.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Samsung kickstarts chip production with 3nm process technology

Samsung kickstarts chip production with 3nm process technology

By Nikita Chaurasia

Samsung Electronics Co Ltd has reportedly declared that it has begun the mass production of chips using advanced 3-nanometre technology. The company is the first in the entire world to do so and is actively looking for new clients to contest with Tai...

Progcap nabs $40Mn in funding round for expansion & product development

Progcap nabs $40Mn in funding round for expansion & product development

By Nikita Chaurasia

Progcap, a pioneer in the field of corporate-driven financing solutions for small and medium-sized businesses (SMBs), has secured $40 million in private equity capital at $600 million valuation. The raised capital forms a part of the Series C exte...

Microsoft solidifies Qatar investment; Unveils new high-tech office

Microsoft solidifies Qatar investment; Unveils new high-tech office

By Nikita Chaurasia

Microsoft, the global tech behemoth, has recently stated that it is expanding its operation in Qatar by unveiling a new Lusail City unit, the firm’s largest and fourth in the country. This new facility forms part of a substantial investment tha...